EGAGenomicsOtherhttps://ega-archive.org/studies/EGAS00001007547EGAEGA study EGAS00001007547Single-cell RNA and TCR sequencing of 40 advanced HCC biopsies.Single cell TotalSeqC protein data of 20 PMBC pools of HCC patientsSingle-cell RNA and TCR sequencing of 37 PBMC pools of advanced HCC patients.restrictedEGAHYCC1, Carcinoma, dTAF[[II]]230, TAF[[II]]250, d230, Liver, SLEB2, Leu2, TAF200, l17, Cell Carcinoma, l(3)84Ab, dTAFII250, Liver Cell, adult hepatoma, BG:DS00004.13, TAFII-250, Hepatomas, TAF250/230, EfW1, Liver Cell Carcinoma, Cell, dTAF230, Cell Carcinomas, dmTAF[[II]]230, TAFII250, RPL23, rpl17a, HCC, Liver Cell Carcinomas, dmTAF1, Taf230, pd-1, p230, Adult Liver Cancer, TAF[[II]]250/230, TFIID, Adult Liver, MAL, PD1, PD-1, TAF250, Carcinomas, Taf[[II]]250, study, Ly101, Taf200, DRCTNNB1A, dTAF[[II]]250, TAF[[II]]230, Adult Liver Cancers, Hepatocellular carcinoma, TFIID TAF250, Liver Cancer, Hepatoma, cel, cell, p32, adult primary hepatocellular carcinoma, Liver Cancers, 60S ribosomal protein L23, HLD5, rpl23, Taf1p, TAF[II]250, Cancers, Adult, CG17603, TAF[[II]], CD279, hPD-1, Hepatocellular Carcinoma, dTAF250, hPD-l, DmelCG17603, Pdc1, TAF1., Taf250, SR3-5, hSLE1, rpl17, Hepatocellular, L17, CD8, Hepatocellular Carcinomas, TAF, TAF230, CancerCPD photolyase activity, PD L1 Inhibitor, mononuclear leukocyte, PhrB photolyase activity, HSN1E, Peripheral Blood Mononuclear Cells, 10X V(D)J, Feature, Blood, Gene Expression Profile, adult hepatoma, Profiles, T-Lymphocyte, Hepatomas, pigmented epithelium, Liver Cell Carcinoma, dmTAF[[II]]230, T Lymphocyte, responsivity, 3, Peripheral Blood Mononuclear Cell, 10X VDJ, NUP96, PD L1 Inhibitors, epithelium, immature T cell, treatment, PD-1 Inhibitors, DRCTNNB1A, TFIID TAF250, Biopsies, Programmed Death-Ligand 1 Inhibitors, cel, T-Cells, Tissue, pigmented retina, adult primary hepatocellular carcinoma, HLD5, T, Adult, Signatures, Chromium Single Cell V(D)J, DNA cyclobutane dipyrimidine photolyase activity, Hepatocellular Carcinoma, SUPPRESSOR OF AUXIN RESISTANCE 3, T Cells, Mononuclear, Immune, Mononuclear Leukocytes, Expression Signature, PD-L1 Inhibitor, disease management, Therapies, Transcriptomes, CXXC finger protein 9, Thymus Dependent Lymphocytes, Therapy, PRE, Carcinoma, dTAF[[II]]230, Liver, Checkpoint Blockade, CTLA-4 Inhibitors, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Expression Profiles, TAF200, Liver Cell, TAFII-250, TAF250/230, PBMC Peripheral Blood Mononuclear Cells, Gene Expression, TAFII250, Immune Checkpoint Blockers, HCC, retinal pigment, T-Cell, CTLA 4 Inhibitor, Expression Signatures, dipyrimidine photolyase (photosensitive), simple tissue, Adult Liver, Programmed Cell Death Protein 1 Inhibitors, Expression Profile, retinal pigment layer, PD-1, Transcriptome Profiles, Carcinomas, ADCADN, T-cell, Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors, PBM cell, UNQ203/PRO229, Hepatoma, DNA (cytosine-5-)-methyltransferase 1, Thymus-Dependent, PD 1 Inhibitor, T-lymphocyte, Features, CG17603, TAF[[II]], Treatments, Thymus-Dependent Lymphocyte, Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor, phr A photolyase activity, T cell, DNA-photoreactivating enzyme, antagonists and inhibitors, Taf250, Patient, SR3-5, PBMCs, Cells, Checkpoint Inhibitors, T Cell, Hepatocellular Carcinomas, Inhibitor, TAF230, peripheral blood mononuclear cell, HYCC1, d230, Thymus-Dependent Lymphocytes, Transcriptome Profile, Cell Carcinoma, Gene, dTAFII250, dominant cleft palate, photoreactivating enzyme activity, PD-L1 Inhibitors, EfW1, PD 1 PD L1 Blockade, deoxyribodipyrimidine photolyase activity, Cell Carcinomas, Aim, AIM, Blockade, Liver Cell Carcinomas, dmTAF1, Taf230, PBMC, peripheral blood mononuclear cell., Adult Liver Cancer, stratum pigmentosa retinae, PD-1 Inhibitor, Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor, TAF250, reactivity, DNMT1, Taf200, MOS3, dTAF[[II]]250, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, isolated, Liver Cancer, DNMT1_HUMAN, PRECOCIOUS, cell, Profile, Liver Cancers, inhibiteur, F23A5.3, Taf1p, Checkpoint Blockers, Programmed Death Ligand 1 Inhibitors, Solution, CTLA-4 Inhibitor, Immune Checkpoint Blockade, API6, dTAF250, 10X Immune profiling, inhibidor, Mononuclear Leukocyte, Clients, mature T cell, PD-1-PD-L1, Characteristics, TAF, T Lymphocytes, F23A5_3, CPI, Lymphocyte, Cancer, DNA MTase HsaI, DNA (cytosine-5)-methyltransferase 1, PD-1-PD-L1 Blockade, inhibitors, TAF[[II]]250, Leukocyte, Transcriptome, whole blood, PBMC cell, DNMT, inhibitor, l(3)84Ab, Checkpoint Inhibitor, BG:DS00004.13, MCMT, Client, Cell, dTAF230, whole transcriptome, Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors, CTLA 4 Inhibitors, MODIFIER OF SNC1, Characteristic, PD 1 Inhibitors, p230, DNA methyltransferase HsaI, Gene Expression Signatures, deoxyribonucleic photolyase activity, TAF[[II]]250/230, TFIID, Gene Expression Signature, T lymphocyte, CXXC9, antagonists, Taf[[II]]250, Peripheral Blood Human Mononuclear Cells, RPE, TAF[[II]]230, Peripheral Blood, Adult Liver Cancers, Hepatocellular carcinoma, CT-2, photolyase activity, Immune Checkpoint Inhibitor, Lymphocytes, TAF[II]250, Cancers, Programmed Cell Death Protein 1 Inhibitor, CXXC-type zinc finger protein 9, p. pigmentosa retinae, Reticuloendothelial System, DmelCG17603, cleft palate, Therapeutic, Checkpoint Inhibition, Gene Expression Profiles, Hepatocellular, Treatment, deoxyribonucleate pyrimidine dimer lyase (photosensitive), response, Signature, CLEC2C, Immune Checkpoint Inhibition, m.HsaI, TAF1falseStudy of PD-1 negative CD8 effector T-cells in advanced HCC with single-cell sequencingImmune checkpoint inhibitors (CPI) have dramatically changed the treatment landscape of advanced HCC (aHCC), but factors associated with response/resistance to CPI remain to be elucidated. The main aim of this project was to identify features associated with response and/or resistance to checkpoint inhibitors in advanced HCC at the single-cell resolution. We subjected both pre-treatment tissue biopsies and serial peripheral blood mononuclear cell (PBMC) samples of aHCC patients (n=44) treated with systemic therapy to droplet-based single-cell transcriptome (scRNAseq) and T-cell receptor sequencing (scTCRseq) using Chromium Single Cell V(D)J Solution. Doing so, we obtained high quality transcriptomic data for tissue biopsies and PBMC samples.2023-11-09 10:15:55EGAS000010075479606EGAD00001011346EGAD00001011347EGAD00001011345EGAC00001003415